Clinical trials: Ocular Pain
Ocular Pain
A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers
Single-Center, Phase 1 study to assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying…
- Trial name
- NCT06978244
- Testing
- BL1332 ophthalmic solution, BL1332 ophthalmic vehicle
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Cataracts
Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo
To evaluate the safety and efficacy of Nepafenac 1 mg/ml Eye Drops, Suspension, compared to Placebo and Ketorolac Trometamol 5 mg/ml Eye Drops, Solution for the prevention and treatment of ocular inflammation and ocular pain…
- Trial name
- NCT00405730
- Testing
- Nepafenac 1mg/ml eye drops, suspension, Ketorolac Trometamol 5 mg/ml eye drops, solution, Nepafenac vehicle eye drops
- Where
- France
- Volunteers
- 227 people
- Sponsor
- Alcon Research
Eye Pain
Study of the ETX-4143 2.0 Device in Subjects With Eye Pain
A prospective early-feasibility study to evaluate the safety and effectiveness of the ETX-4143 2.0 device. The device is intended to treat subjects with eye pain
- Trial name
- NCT06479382
- Testing
- ETX-4143 2.0
- Where
- 4 sites in Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- EyeCool Therapeutics, Inc.
Cataract
Nepafenac Compared to Placebo for Ocular Pain and Inflammation
The purpose of this study was to demonstrate that Nepafenac Ophthalmic Suspension, 0.1% is superior to Nepafenac Vehicle (placebo) for the prevention and treatment of ocular inflammation and pain associated with cataract surgery…
- Trial name
- NCT01426854
- Testing
- Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Vehicle Ophthalmic Solution
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Alcon Research
Eye Pain
A Clinical Study to Determine What Effect the EyeCool Treatment Has on the Eye's Surface Anatomy and Inflammation Response After Being Treated for Having Chronic Ocular Surface Pain (COSP)
The goal of this clinical trial is to understand what effect a cold treatment with an investigational device, ETX-4143, has on the anatomical structures and the inflammatory response of the surface of the eye in those people who…
- Trial name
- NCT07059754
- Testing
- Topical Ophthalmic Cooling
- Where
- Australia
- Volunteers
- 5 people
- Sponsor
- EyeCool Therapeutics, Inc.
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Cataract
A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery
This is a safety and efficacy study of a Dexamethasone Drug Delivery System for anterior segment inflammation and pain following cataract extraction with lens implantation.
- Trial name
- NCT01605942
- Testing
- Dexamethasone Drug Delivery System
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Allergan
Post Surgical Ocular Inflammation and Pain
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
The primary objective of the study is to investigate the efficacy and safety of KPI-121 1.0% ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.
- Trial name
- NCT02793817
- Testing
- KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of KPI-121 Ophthalmic Suspension dosed BID
- Where
- 35 sites in United States
- Volunteers
- 520 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Pain, Inflammation
Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery
This is an efficacy study of Bromfenac Ophthalmic Solution in cataract surgery.
- Conditions
- Pain, Inflammation, Cataract
- Trial name
- NCT01367249
- Testing
- Bromfenac Ophthalmic Solution
- Where
- United States
- Volunteers
- 440 people
- Sponsor
- Bausch & Lomb Incorporated
Chronic Ocular Pain
Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)
The study was designed to demonstrate the safety and efficacy of two dose concentrations of SAF312 eye drops (5 mg/mL and 15 mg/mL) in subjects with CICP persisting at least for 4 months after refractive or cataract surgery and…
- Trial name
- NCT04630158
- Testing
- SAF312
- Where
- 28 sites in United States, Japan and 1 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Pain
Evaluation of Vitrase as a Spreading Agent
The purpose of this study is to determine whether Vitrase (hyaluronidase for injection) is effective as a spreading agent for other injected drugs prior to ocular surgery
- Trial name
- NCT00198484
- Testing
- Vitrase
- Where
- 18 sites in United States
- Volunteers
- 108 people
- Sponsor
- Bausch & Lomb Incorporated
Inflammation, Pain
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery
The objective of this study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT01298752
- Testing
- Mapracorat, Vehicle
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Bausch & Lomb Incorporated
Ocular Pain, Dry Eye
Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers
The purpose of this study is to determine whether SYL1001 is safe for the prevention and treatment of ocular pain and dry eye syndrome.
- Trial name
- NCT01438281
- Testing
- SYL1001
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sylentis, S.A.
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- Kauai (NCT02188160)
- Testing
- KPI-121
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Migraine
Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab
Migraine is a very common, neurological disorder, characterized by recurrent episodes of headache, potential progression to more frequent and severe attack patterns, and associated symptoms.
- Trial name
- COMIG (NCT04114630)
- Testing
- erenumab 70mg/mL
- Where
- 27 sites in Spain
- Sponsor
- Novartis Pharmaceuticals
Ocular Pain, Dry Eye Syndrome
Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain
The aim of this pilot study is to compare the analgesic effect of two strengths of SYL1001 eye drops versus placebo in patients with ocular pain associated with Dry Eye Syndrome. General and local tolerability are also evaluated.
- Trial name
- NCT02455999
- Testing
- SYL1001
- Where
- 6 sites in Estonia, Spain
- Volunteers
- 66 people
- Sponsor
- Sylentis, S.A.
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Cataract
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Cataract surgery is one of the most common surgical procedures performed worldwide. In fact, in 2017, 3.8 million cataracts procedures were performed in the US.
- Trial name
- CLOSE-1 (NCT04246801)
- Testing
- Clobetasol propionate, Vehicle
- Where
- 22 sites in United States
- Volunteers
- 250 people
- Sponsor
- Salvat
Inflammation, Pain
Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate ophthalmic gel
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT01996839
- Testing
- Loteprednol Etabonate Gel (BID), Loteprednol Etabonate Gel (TID), Vehicle (BID)
- Where
- United States
- Volunteers
- 514 people
- Sponsor
- Bausch & Lomb Incorporated
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
MIRAGE Study: Clinical Outcomes of the Mamba Sirolimus-Eluting PTCA Balloon
This Clinical Evaluation Report (CER) covers the Mamba Sirolimus-Eluting PTCA Balloon catheter intended for the treatment of coronary artery disease in de novo or in-stent restenosis lesions.
- Trial name
- NCT07326735
- Testing
- Mamba Sirolimus-Eluting PTCA Balloon, Percutaneous Coronary Angioplasty with Sirolimus-Coated Balloon
- Where
- 2 sites in Burma, Malaysia
- Volunteers
- 360 people
- Sponsor
- Frisch Medical Device Private Limited